TABLE 1.

Summary of the effect of treatment on pre-bronchodilator forced expiratory volume in 1 s (FEV₁), asthma exacerbations and mortality

Study [ref.]	Subjects n	Duration weeks	Asthma severity#	Treatment group	Change from baseline in pre-bronchodilator FEV1 mL	Exacerbations¶		Mortality %+
						Overall	ED and hospitalisation
Busseet al. [79]	36 010	26	Moderate	ICS	Not reported	11.7%	0.60%	0
				ICS/LABA	Not reported	9.8%	0.66%	0
DREAM [80]	616	52	Severe	Placebo	60	2.40	0.43	0
				Mepolizumab	115–140	1.15–1.46	0.17–0.25	1
MENSA [81]	576	32	Severe	Placebo	86	1.74	0.20	1
				Mepolizumab	183–186	0.83–0.93	0.08–0.14	0
MUSCA [82]	551	24	Severe	Placebo	56	1.21	0.10	0
				Mepolizumab	176	0.51	0.03	0
CALIMA [83]	1306	56	Severe	Placebo	215§	0.93§	0.04§	0
				Benralizumab	330–340§	0.60–0.66§	0.04–0.05§	0
SCIROCCO [84]	1205	48	Severe	Placebo	239§	1.33§	0.18§	0
				Benralizumab	345–398§	0.65–0.73§	0.06–0.11§	0
Castroet al. [85]	953	52	Severe	Placebo	120	1.81	0.12	0
				Reslizumab	220	0.84	0.077	0
QUEST [86]	1902	52	Moderate-to-severe	Placebo	180–210ƒ	0.87–0.97	0.065	0
				Dupilumab	320–340ƒ	0.46–0.52	0.035	0

Ranges indicate results with different doses/routes of administration. ED: emergency department; ICS: inhaled corticosteroid; LABA: long-acting β₂-agonist. ^#: asthma severity based on treatment requirements and prior asthma exacerbation rates; ^¶: events are expressed as episodes per patient per year, unless otherwise specified; ⁺: rounded to 0 decimal places; ^§: data are for the subgroup with severe asthma and eosinophils ≥300 cells·µL⁻¹ (n=728 in CALIMA and n=809 in SCIROCCO); ^ƒ: change from baseline at week 12 (all other FEV₁ data presented as change from baseline at the final study visit).